Flavay® is the productused in the actual experimentsby
which
Dr. Jack Masquelier established and patented the
"radical scavenger effect."
"Radical Scavenger
Effect"
Protected by U.S. Patent No. 4,698,360
Originally patented and licensed in France for therapeutic
uses, Flavay® is the very productused in the actual
experimentsby which Dr. Jack Masquelier established and
patented the "radical scavenger effect."
"[A] method for preventing and fighting
the harmful biological effects of free radicals
in the organism of warm blooded animals and more especially
human beings, namely cerebral involution, hypoxia following
atherosclerosis, cardiac or cerebral infarction, tumour
promotion, inflammation, ischaemia, alterations
of the synovial liquid, collagen degradation,
among others. The method consists in administering to
said animals and especially to human beings an amount,
efficient against said effects, of a plant extract with
a proanthocyanidins content which has a radical
scavenger effect"Dr. Jack Masquelier,
U.S. Patent No. 4,698,360.
During any challenge to your immune systembecause of
disease, infections, toxic exposure, stress or agingyou
need the extra antioxidant power in Flavay®
to help scavenge the free radicals naturally produced
by the immune system's cells during warfare.
Antioxidants vs. Free Radicals
Antioxidants fight corrosive and destructive forces that constantly
work to break down our bodies. Overwhelming scientific evidence
demonstrates that those of us who eat a diet rich in antioxidants
and take antioxidant supplements will live longer and healthier
lives. Working as a defensive army, antioxidants work together
in the body to maintain our health and vigor by protecting us
from damage caused by rampaging free radicals which, like terrorists,
injure healthy cells and tissues.
Don't underestimate the threat that free radicals pose to our
health. Contemporary scientists now believe that free radicals
are causal factors in nearly every known disease, from heart
disease to arthritis to cancer to cataracts to the aging process
itself.
Where do free radicals come from? The body produces free radicals
in the normal course of energy production and there are substances
in our environment (chemicals in our foods and beverages, medications,
extremely reactive air pollutants from vehicle exhaust, and
even solar radiation) that trigger the production of free radicals.
Free Radicals: Both Foe
and Friend
to the Immune System and Brain Function
When the body fights off an infection, the immune system's
cytokines go to work, sending messages to the brain that cause
more white blood cells to mobilize. The more white blood cells
your body activates, the more free radicals they produce, like
pellets of poison, that go to work to destroy invaders by breaking
down the genetic material of bacteria, toxins, and viruses.
When functioning properly, the immune system is capable of
identifying foreign invaders such as viruses and bacteria and
our immune components do not turn against our own body's cells.
Unfortunately, however, free radicals can interfere with the
biological components of our healthy cells in the same way they
destroy invaders, literally dismantling the body's essential
cellular proteins, fatty cell membranes and DNA.
The most important natural defenses we have against free radical
damage are our body's natural "antioxidants," a broad
range of chemical substances that all have one thing in common:
they ward off free radical damage to cells. However, in many
neurological diseasesincluding Parkinson's, Alzheimer's,
chronic fatigue, and multiple sclerosisthe brain's specialized
antioxidant mechanisms fail. The cause of the failure might
be genetic, environmental, or even dietary, but the consequences
are the same: unchecked free radical activity on the brain.
Some free radicals are beneficial in the body, such as nitric
oxide, which acts as a neurotransmitter when the immune system
is functioning properly. Unfortunately, the excessive production
of nitric oxide can also be blamed for throwing the brain-immune
systems off kilter and causing some of the brain's worst free
radical damage. Over the past decade, scientists have shown
that the production of nitric oxide through a combination of
immune and nervous system activityoften sparked by an
infection, exposure to a toxin, or as part of the aging processplays
a key role in the development of neurological diseases.
Free Radicals: Both Foe
and Friend
to the Cardiovascular System
Free radicals are involved in the progression of heart disease
in several different ways. Heart disease begins with the oxidation
of LDL (low-density lipoproteins) cholesterol which leads to
the formation of plaque in the arteries. If an artery becomes
clogged with plaque, the result can be a heart attack (a sudden
loss of blood and oxygen to the heart) or a stroke (loss of
blood to the brain). Much of the damage that occurs in both
heart attacks and strokes is caused by reperfusion injury:
the burst of superoxide free radicals that flow in as the blood
flow resumes.
Contemporary scientific studies have established another way
in which free radicals can promote atherosclerosis (hardening
of the arteries), and how one free radical in particularnitric
oxidemay play a central role. Nitric oxide is essential
for normal blood circulation as it controls the muscular tone
of blood vessels and regulates circulation and blood flow. But
excessive amounts of nitric oxide can be very destructive as
it can restrict blood flow and promote production of more free
radicals, contributing to heart disease and stroke. Thus, in
order to have good circulatory health, the body must maintain
the right balance of nitric oxideand that's the role of
the antioxidants and their boosters.
Free Radicals and Chronic
Inflammation
Inflammation is caused by the overproduction of free radicals
in a specific area of the body. The inflammatory response is
a factor in arthritis, an umbrella term for more than 100 different
diseases that produce either inflammation of the connective
tissue (joints and tendons) or degeneration of the articular
cartilage (a wearing down of the protective covering that cushions
the end of bones, allowing bones to rub together without causing
damage to the joints). When joints become arthritic, they become
inflamed and enlarged, interfering with the normal flow of blood.
For example, bending an arthritic knee restricts blood flow
to the area. As in the case of stroke and heart attack, when
blood flow is cut off, it sets into motion a chain of events
that will lead to a burst of free radicals when blood flow returns.
The proliferation of free radicals causes a one-two punch as
the area to become even more inflamed, contributing to the degeneration
of the joint, which becomes more swollen and worn down.
The key to good health is to maintain the right balance between
antioxidants and free radicals.
Flavay® is Your Best Weapon
Against Toxic Free Radicals
Flavay® is superior to other
antioxidants because its protective effects are multiplied in
the body: while it provides its own, powerful antioxidant protection,
it also supports the dynamic interplay between other antioxidants
in the body. Flavay's ability to recycle, or regenerate
vitamins C and E after they have quenched free radicals vastly
extends their unique antioxidant powers, helping the body to
maintain its synergistic antioxidant balance.
Flavay® is rapidly absorbed and very quickly distributed
throughout the body. As a free radical fighter, Flavay®
comes to the aid of the body more quickly than other antioxidants,
reducing the potential for free radical damage and the ravages
of aging. Flavay® also possesses more reactive sites for
neutralizing free radicals than other known antioxidants. Furthermore,
Flavay® permits reactivity with both positively and negatively
charged free radical species. What this means is that Flavay®
can quench or scavenge (neutralize)
a broad variety of free radicals. Highly reactive as an antioxidant
in both lipid (fat) and aqueous (water) phases, Flavay®
neutralizes oxygen free radicals and is a valuable protector
of healthy cells in a variety of internal conditions. This is
a unique property among antioxidants, as most work either in
lipid or aqueous phases, but not both.
Flavay® helps to modulate the effects of nitric oxide,
an important free radical produced by the body. As discussed
above, some nitric oxide is essential, but too much can kill
cells. Research demonstrates that Flavay® can help to maintain
the optimal level of this free radical by helping the body produce
adequate levelsand neutralize nitric oxide where it does
harm.
Research also demonstrates that Flavay® can quench superoxide
and the hydroxyl radical. This is extremely important. Of all
the free radicals formed in the body, the hydroxyl radical is
the most dangerous because it can directly attack DNA. As a
free radical scavenger, Flavay® is like an antioxidant
prize fighter that can successfully take on all challengers,
big or small, in any kind of weather.
Antioxidants Work Together
in the BodyNot Alone
Current research demonstrates that key antioxidants and their
co-factor nutrients work synergistically with one another in
the body. Flavay Plus® utilizes
this dynamic interplay among the antioxidants and their co-factor
nutrients with a synergistic blend of Flavay® and antioxidant
vitamins and minerals and phytonutrients; formulated to boost
the brain and immune functionsthereby benefiting the whole
body.
Patented Antioxidant Power—Plus
Flavay’s® strong antioxidant power is patented—as
a scavenger of the free radicals that play a major
role in the degradation of collagen and the initiation, duration
and breakdown of inflammation. That means that your immune system
works better, your joints hurt less, and your blood flows better,
all because of Flavay®.
And now, Flavay Plus® takes
advantage of the dynamic interplay between Flavay® and
the other antioxidant nutrients and their co-factors in a blend
that provides you and your family with the best that nutritional
science has to offer for antioxidant protection—in a convenient,
cost effective capsule.
Statements made herein have not been
evaluated by the Food and Drug Administration. These products are not intended
to diagnose, treat, cure or prevent any disease.
Masquelier, J. Plant extract
with a proanthocyanidins content as a therapeutic agent having
radical scavenging effect and use thereof. U.S. Patent No. 4,698,360,
1987.
Masquelier, J. A lifetime devoted to OPC and Pycnogenols. Alfa
Omega Editrice, Pub., 1996.
Schwitters, B., Masquelier, J. OPC in practice. Alfa Omega Editrice,
Publishers, 1995.
Kilham, C., Masquelier, J. OPC: The miracle antioxidant. Keats
Publishing, Inc., 1997.
Mindell, E., et al. Earl Mindells vitamin bible for the
21st century. Warner Books, Inc., 1999.
Passwater, R.A. The antioxidants: the nutrients that guard your
body. Keats Publishing, Inc., 1985.
Barilla, J. et al. The nutrition superbook: volume 1: the antioxidants.
Keats Publishing, Inc., 1995.
Lieberman, S., et al. The real vitamin & mineral book: going
beyond the RDA. Avery Pub., 1990.
Facino RM, et al. Free radical scavenging action and anti-enzyme
activities of procyanidines from Vitis vinifera. A mechanism for
their capillary protective action. Arzneimittelforschung, 44:
592-601, 1994.
Kuttan R, et al. Collagen treated with catechin becomes resistant
to the action of mammalian collagenase. Experientia, 37: 221-223,
1981.
Masquelier, J., et al. Stabilization du collagene par les oligomeres
procyanidoliques. Acta Therapeutica, 7:101-105, 1981.
Masquelier, J. Aspects pharmacologiques nouveaux de certains flavonoides.
A Vie Medical 12:1969.
Laparra, J., et al. Etude pharmaco-cinetique des oligomers procyandoliques
totaux du raisin. Acta Therapeutica, 4, 1978.
Laparra, J., et al. Etude pharmacocinetique des oligomeres flavonoliques.
Plantes med et phyto, Tome XI, pp. 133-142, 1977.
Robert A.M.; Groult, N.; Six, C.; Robert, L. Etude de laction
des oligomeres procyanidoliques sur des cellules mesenchymateuses
en culture. Ii lattachment des fibres elastiques aux cellules.
(Study of the effect of procyanidolic oligomers on mesenchymal
cells in culture. Ii attachment of elastic fibers to the cells.)
Pat Biol, (30)6:601-7, 1990.
Porter, Lawrence J., Wong Rosalind Y. Chan, Bock G. The molecular
and crystal structure of (+)-2,3-trans-3,4-trans-leucocyanidin
[(2r,3s,+r)-(+)-3,3, 4.4, 5.7-Hexahydroxyflavan]
dihydrate, and comparison of its heterocyclic ring conformation
in solution and the solid state. Journal of the Chemical Society;
Perkin Transactions I 1985. pp. 1413-17.
Masquelier, J. Proanthocyanidins et radicaux libres. 1985.
Uchida, S., et al. Condensed tannins scavenge active oxygen free
radicals. Med Sci Res, (15) 1987. pp. 831-832.
Ariga, T. Radical scavenging action and its mode in procyanidins
b-1 and b-3 from azuki beans to peroxyl radicals. Agric Biol Chem,
54(10) 1990. pp. 2499-2504.
Da Silva, R., et. al. Radical scavenger capacity of different
procyanidins from grape seeds. Presented at a symposium, Free
radicals in biotechnology and medicine. Royal Society Of
Chemistry, London January 1990, pp. 79-80.
Bauman, J., Wurm, G., Bruchhausen, F. Hemmung der prostagladinsynthetase
durch flavonoide und phenolderivate im vergleich nit deren 02
radikalfangereigenschaften Arch Pharm, (Weinheim) 313 (1980)
pp. 330-337.
Lombard, J., et al. The brain wellness plan. Kensington Pub. Corp.,
1998.
Facino, R.M., et al. Free radical scavenging action and anti-enzyme
activities of procyanidines from vitis vinifera. A mechanism for
their capillary protective action. Arzneimittelforschung, 44:
592-601, 1994.
Kuttan, R., Donnelly, P.V., Di Ferrante, N. Collagen treated with
catechin becomes resistant to the action of mammalian collagenase.
Experientia, 37: 221-223, 1981.
Masquelier, J. Procyanidolic oligomers. J Parums Cosm Arom, 95:
89-97, 1990.
Tixier, J.M., et al. Evidence by in vivo and in vitro studies
that binding of pycnogenols to elastin affects its rate of degradation
by elastases. Biochem Pharmacol, 33: 3933-3939, 1984.
Kakegawa, H., et al. Chem. Pharm. Bull. 33:5079, 1985.
Harmand, M.F., Blanquet, P. The fate of total flavanolic oligomers
extracted from vitus vinifera l. in the rat. European
Journal of Drug Metabolism and Pharmaccokinetics. 1978, No. 1
pp. 15-30.
Delrieu, P., Ding J., Escande, B., Samain, D. Free-radical scavenging
activity of proanthocyanidolic oligomers encapsulated in glycospheres:
an in vivo and in vitro study. Cosmetology Department & S
Biovectors, Ramonville St. Agne France. pp. 1-9.
Meunier, M.T., Villie, F., et al. Inhibition of angiotensin i
converting enzyme by flavanolic compounds: in vitro and in vivo
studies. Planta Medica, May 26, 1986. pp. 12-15.
Barbier, A., et al. Activite angioprotectrice des oligomeres procyanidolques
chez lanimal-oedenme de la patte. Sanofi Res Toul Cedex
Fr, pp31-40.
Barbier, A., et al. Activite angioprotectrice des oligomeres procyanidolques
chez lanimal-activite aniagoniste vis-a-vis des mediateurs
de linflamation. Sanofi Res Toul Cedex Fr, pp. 31-40.
Dubos, C., Durst, G., Hugonot, H. Evolution de la resistance capillaire,
spontanement ou artificiellement diminuee par laction dune
substance capillaro-toxique chez des personnes agees--action benefique
dun agnet actif sur la micro-circulation: lEndotelon.
Inform. Therapeut. 1980. pp. 302-305.
Dartenuc, J.Y., et al. Resistance capillaire en geriatrie etude
dun microangioprotecteur-Endotelon. Bordeaux Med. 13:903-7,
1990.
Lagrue, G., Olivier-Martin, F., Grillot, A. Etude des effets
des oligomeres du procyanidol sur las resistance capillaire dand
lhypertension arterielle et certaines nephropathies.
Sen. Hosp. Paris 18-25 Septembre, 1981.
Beylot, C., Bioulac, P. Essai therapeutique dun angioprotecteur
peripherique, lEndotelon. Actualite Therapeutique Gaz. Med.
de France (87)22:2919-24, 1980.
Lesbre, F.X., Tigaud, J.D. Effect de lEndotelon sur lindice
de fragilite capillaire dan une population specifique: les sujets
cirrhotiques. Gaz. Med. de France, (90)24 1983.
Sarrat, L. Abord therapeutique des troubles fonctionnels des membres
inferieurs par un microangioprotecteur lEndotelon. Bordeaux
Med, 11:685-8, 1981.
Delacroix, P. Etude en double aveugle de lEndotelon dans
linsuffisance veineuse chronique. Therapeutique, la Revue
de Medicine, (27-28) Sept. 1981. pp. 1793-1802.
Thebaut, J.F, Thebaut, P., Vin, F. Etude de lEndotelon dand
les manifestations fonctionnelles de linsuffisance veineuse
peripherique-resultats dune etude en double aveugle portant
sur 92 patients. Gazette Medicale, (92)1, 1985. pp. 96-100.
Wegrowski, J., Robert, A.M., Maczar, M. The effect of procyanidolic
oligomers on the composition of normal and hypercholesterolemic
rabbit aortas. Biochem. Pharmacol, (33)21. 1984. pp. 3491-3497.
Chang, W.C., Hsu, F.L. Inhibition of platelet aggregation and
arachidonate metabolism in platelets by procyanidins. Prostagland
Leukotri Essent Fatty Acids, 38:181-8, 1989.
Masquelier, J. Pycnogenols: recent advances in the therapeutical
activity of procyanidins. Supplement of Planta Medica, Journal
of Medicinal Plant Research and Journal of Natural Products, July
1980 pp. 243-256.
Henning, B., et al. Lipid peroxidation and endothelial cell injury:
implications in atherosclerosis. Free Rad Path & Med, (4)1988
pp. 99-106.
Masquelier, J. Les procyanidols du vin leur role dans lalcoolisme.
pp. 88-93.
Gazave, J.M. Notions recentes sur les capillaires
unpub. bulletin from the Laboratoire De Physiologie Patholigie
pp. 26-29.
Ruf, J.C. Wine and polyphenols related to platelet aggregation
and atherothrombosis. Office International Vigne et du Vin, Nutrition
and Health Unit, Paris France; Drugs under Experimental and Clinical
Research (Switz.) 25/2-3 (125-131), 1999.
Blaszo, G. Gabor, M. Oedema-inhibiting effect of procyanidin.
Acta Physiologica Academiae Scientiarum Hungaricae, Tomus 56(2):235-240,
1980.
Tayau, M.F, LeFevre, G. Action du leucocyanidol sur lhyalaluronidase.
Bull Soc Pharm Bordeaux, 95:132-136, 1956.
Lamy, M. Utilization des oligomeres procyanidoliques en gynecologie.
Essai Therapeutique Tomel (14) Sept. 2, 1981. pp. 1021-22.
Henriet, J.P Une Etude Exemplaire Pour Un Phlebotrope: letude
EIVE. Unpub., pp. 77-83.
Pfister, A., Simon, M.T., Gazave, J.M. Sites de fixation des oligomeres
procyanidoliques dans la paroi des capillaires sanguins du poumon
decobaye. Acta Therapeutica (8) 1982. pp. 223-237.
Kuttan, R., Donnelly, P., Di Ferrante, N. Collagen treated
with (+) -catechin becomes resistant to the action of mammalian
collagenase. Laboratory of Connective Tissue Research, Dept.
of Biochem. Baylor Col. of Med., Houston TX. 28, May, 1980.
Gendre, P., Laparra, J., Barraud, E. Effect protecteur des
oligomeres procyanidoliques sur le lathyrisme experimental chez
le rat. Ann. Pharm. Francaises, (43)1, 1985 pp. 61-73.
Corbe, C., Boissin, J.P., Siou, A. Light vision and chorioretinal
circulation. Study of the effect of procyanidolic oligomer (Endotelon).
Jn. Fr. Opthalmol, (11)5:453-460, 1988.
Boissin, J.P., Corbe C., Siou, A. Chorioretinal circulation and
dazzling: use of procyanidol oligomers (Endotelon). Bull Soc Ophtalmol
Fr, 88(2):173-4, 177-9, 1988.
Proto, F. et al. Electrophysical study of vitis vinifera procyanoside
oligomers effects on retinal function in myopic subjects. Ann
Ott Clin Ocul, 114:85-93, 1988.
Saracco, J.B., Estachy, G.M. Etude d lEndotelon en opthalmologie.
Gaz Med de France, 88:2035-2038, 1981.
Scharrer, A., Ober, M. Anthocyanosides in the treatment of retinopathies.
Klin Monatsbl Augenheilkd, 178:386-389, 1981.
Corbe, C., et al. Microangiopathy of the retina. J. Fr. Opthalmol,
11:453, 1988.
Verin, M.M., Vildy, A., Maurin, J.F., Retinopathies et O.P.C.
Bordeaux Medicale, (16)11. pp. 1467-74, 1978.
Soyeux, A. et al. Endotelon. Diabetic retinopathy and hemorheology.
Bull Soc Ophtalmol Fr. 87(12):1441-4, 1987.
Fromantin, M. Les oligomeres procyanidoliques dans le traitement
de la fragilite capillaire et de la retinopathie chez les diabetiques.
A propos de 26 cas. Med Int, 16(11):432-434, Nov. 1981.
Arne, J.L. Contribution a letude des oligomeres procyanidoliques:
Endotelon, dans la retinopathie diabetique (a propos de 30 observations).
Gaz. Med. de France, Vol. 89, No. 30, Oct. 8, 1982.
Baruch, J. Effect of Endotelon in postoperative edema. Results
of a double-blind study versus placebo in 32 female patients.
Ann Chir Plast Esthet 29(4):393-5, 1984.
Rao, C.N. et al. Influence of bioflavonoids on the collagen metabolism
in rats with adjuvantinduced arthritis. Ital J Biochem. 30:54-62,
1981.
Gabor, M. Pharmacologic effects of flavonoids on blood vessels.
Angiologica, 9:355-374, 1972.
Havsteen, B. Flavonoids, a class of natural products of high pharmacological
potency. Biochem Pharmacol, 32:1141-48, 1983.
Reimann, H.J., Lorenz, W., Fischer, M., Frölich, R., Meyer,
H.J. Berkhauser Verlag, Vol. 7/1, Univ. of Marburg/Lahn, Ger.,
1977.
Masquelier, J. Action protectrice du vin sur lulcere gastrique.
Resultats, p. 61.
Amella, M., et al. Inhibition of mast cell histamine release by
flavonoids and bioflavonoids. Planta Medica, 5116-20, 1985.
Packer, L., et al. The antioxidant miracle: your complete plan.
John Wiley & Sons, Inc., 1999.
Shaw, R. How [Australian] PycnoGenol [MASQUELIERs®]
Helps Sports People.
Masquelier, J. Procyanidolic oligomers (leucocyanidins). Parfums
Cosmet Arom 95:89-97, 1990.
Pecking, A., Desprez-Curely, J.P., Megret, G. Oligomers procyanidoliques
(Endotelon) dans le traitement des lymphoedemes post-therepeutiques
de members superieurs. Symposium Satellite, Congres International
dAngiologie, Toulouse, France, 4-7 Oct. 1989.
Fahey, T.D., Pearl M. Hormonal effects of phosphatidylserine during
2 weeks of intense training. Abstract submitted to national meeting
of the Amer College of Sports Medicine, June 1998.
Monteleone, P., Maj, M., Beinat, L., Natale, M., Kemali, D. Blunting
by chronic phosphatidylserine administration of the stress-induced
activation of the hypothalamo-pituitary-adrenal axis in healthy
men. Eur J Clin Pharm 43: 385388, 1992.
Fahey, T.D., et al. The hormonal and perceptive effects of phosphatidylserine
administration during two weeks of resistive exercise-induced
overtraining. Bio of Sport 15(3):135-44, 1998.
Laparra, J., Michaud, J. Masquelier, J. Action des oligomeres
procyanidoliques sur le cobaye carence en vitamin c. Tavaux Originaux,
University of Bordeaux, 1976.
Masquelier, J. Action comparee de divers facteurs vitaminiques
p sur loxydation de lacide ascorbique par les ions
cuivriques. Bull. de la Societe de Chimie Biologique XXXIII (3-4)
1951. pp. 302-304.
Masquelier, J. Action comparee de divers facteurs vitaminiques
p sur lacide ascorbique-oxydase. Bull. de la Societe de
Chimie Biologique XXXIII (3,4) 1951. pp.304-306
Kakegawa, H., Matsumoto, H., Endo, K., Satoh, T., Nonaka, G.,
Mishioka, I. Inhibitory effects of tannins on hyaluronidase
activation and on the degranulation from rat mesentery mast cells.
Chem. Pharm. Bull. 33(11)1985. 5079-5082.
Reiman, H.J., Lorenz, M., Fischer, R., Frolich, H., Meyer, J.
Histamine and acute haemorrhagic lesions in rat gastric
mucosa: prevention of stress ulcer formulation by (+)-catechin,
an inhibitor of specific histidine decarboxylase in vitro.
Dirkhauser Verlag,Vol. 7/1, 1977.
Pariente, J.J. Parientl-Amsellem, J. Les oedemes post-traumatoqies
chez le sportif: essai controle de lEndothelon. Actualite
Therapeutique 90(3) 2/11 1983 pp. 231-235.
Masquelier, J., et al. Flavonoids et Pycnogenols Int
J Vit Nut Res, (49)3:307-311, 1979.
Yu, C. L. et al. Mutagenicity of proanthocyanidins. Food Chem.
Toxicol. 25(2):135-9, 1987.
Pantaleoni, G.C., Quaglino, D. Univerisity of Aquila Pharmacol-Toxicologica
Report, 1971.
Laparra, J., et al., Acta Therapeutica, 4:233, 1978.
Volkner, Wolfgang Muller, Ewald, Micronucleus assay in bone marrow
cells of the mouse with Pycnogenol. Cytotest Cell Research GmbH
& Co., projects 143010 & 143021; Feb. 1989.
Acute and chronic toxicity tests. International Bio-Research,
Inc., Hanover, Germany, 1967-1971.
Dumon, M., Michaud, J., Masquelier, J. Proanthocyanidin content
in vegetable extracts to be used in the preparation of medicines.
Bull. Soc. Pharm. Bordeaux, 129:51-65, 1990.